This company has been marked as potentially delisted and may not be actively trading. NASDAQ:RXDX Prometheus Biosciences (RXDX) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About Prometheus Biosciences Stock (NASDAQ:RXDX) Get Prometheus Biosciences alerts:Sign Up Key Stats Today's Range$199.92▼$199.9250-Day Range$192.50▼$199.9252-Week Range$23.27▼$199.98VolumeN/AAverage Volume913,102 shsMarket Capitalization$9.56 billionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Prometheus Biosciences, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of novel therapeutics for the treatment of inflammatory bowel diseases (IBD). Its lead product includes PRA023, a humanized IgG1 monoclonal antibody (mAb), which is in Phase IIa clinical trial for the treatment of ulcerative colitis and Crohn's disease, as well as systemic sclerosis-associated interstitial lung disease. The company also develops PR300, a G-protein coupled receptor modulator for IBD and potentially other immune-mediated diseases; PRA052, an anti-CD30L mAb for IBD; PR1100, an anti-cytokine receptor mAb for IBD and other immune-mediated diseases; and PR2100, an anti-inflammatory cytokine mAb for IBD, and inflammatory and fibrotic diseases. It has a diagnostics development and collaboration agreement with Takeda Pharmaceutical Company Limited; co-development and manufacturing agreement with Dr. Falk Pharma GmbH for PRA052; license agreement with Cedars-Sinai Medical Center; and strategic collaboration with Millennium Pharmaceuticals, Inc. The company was formerly known as Precision IBD, Inc. and changed its name to Prometheus Biosciences, Inc. in October 2019. Prometheus Biosciences, Inc. was incorporated in 2016 and is headquartered in San Diego, California. As of June 16, 2023, Prometheus Biosciences, Inc. operates as a subsidiary of Merck & Co., Inc. Read More Receive RXDX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Prometheus Biosciences and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. RXDX Stock News HeadlinesEQS-News: Abivax Announces Former Prometheus COO, Mark Stenhouse, Appointed as Board Observer & Advisor to AbivaxNovember 14, 2024 | markets.businessinsider.comAbivax Announces Former Prometheus COO, Mark Stenhouse, Appointed as Board Observer & Advisor to AbivaxNovember 14, 2024 | markets.businessinsider.comMiss This IRS Strategy Now, Regret It LaterWith Donald Trump back in the White House, many believe an economic revival could be underway — but it also brings new risks for retirement savers. Traditional 401(k)s and IRAs may leave investors more exposed than they realize. That’s why a Trump-backed IRS strategy is gaining attention. It allows everyday Americans to reposition their retirement savings into real assets like gold and silver — offering both protection and potential upside. A new 2025 Wealth Protection Guide explains exactly how it works. | American Alternative (Ad)Cormorant Private Healthcare Fund III LP's Net WorthMarch 6, 2024 | benzinga.comPrometheus Biosciences: 8.5% IRR And Closing In A MonthMay 30, 2023 | seekingalpha.comPrometheus Biosciences (NASDAQ: RXDX)May 28, 2023 | fool.comPrometheus Biosciences gains after HSR waiting for sale to Merck expiresMay 23, 2023 | msn.comSHAREHOLDER ALERT: Weiss Law Investigates Prometheus Biosciences, Inc.May 23, 2023 | barrons.comSee More Headlines RXDX Stock Analysis - Frequently Asked Questions How were Prometheus Biosciences' earnings last quarter? Prometheus Biosciences, Inc. (NASDAQ:RXDX) released its quarterly earnings results on Tuesday, May, 9th. The biopharmaceutical company reported ($0.86) earnings per share for the quarter, beating analysts' consensus estimates of ($0.92) by $0.06. The firm's revenue was down 71.8% compared to the same quarter last year. Does Prometheus Biosciences have any subsidiaries? The following companies are subsidiaries of Prometheus Biosciences: Prometheus Laboratories Inc.. When did Prometheus Biosciences IPO? Prometheus Biosciences (RXDX) raised $126 million in an IPO on Friday, March 12th 2021. The company issued 7,400,000 shares at $16.00-$18.00 per share. SVB Leerink, Credit Suisse, Stifel and Guggenheim Securities served as the underwriters for the IPO. What other stocks do shareholders of Prometheus Biosciences own? Based on aggregate information from My MarketBeat watchlists, some other companies that Prometheus Biosciences investors own include Meta Platforms (META), Tesla (TSLA), NVIDIA (NVDA), Advanced Micro Devices (AMD), Netflix (NFLX), Visa (V) and Moderna (MRNA). Company Calendar Last Earnings5/09/2023Today10/12/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolNASDAQ:RXDX CIK1557421 Webignyta.com Phone858-422-4300FaxN/AEmployees97Year Founded1995Profitability EPS (Trailing Twelve Months)($3.52) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$141.75 million Net Margins-3,768.76% Pretax Margin-3,768.76% Return on Equity-33.50% Return on Assets-29.59% Debt Debt-to-Equity Ratio0.04 Current Ratio37.56 Quick Ratio37.56 Sales & Book Value Annual Sales$6.81 million Price / Sales1,403.55 Cash FlowN/A Price / Cash FlowN/A Book Value$16.12 per share Price / Book12.40Miscellaneous Outstanding Shares47,810,000Free Float46,187,000Market Cap$9.56 billion OptionableNot Optionable Beta-0.49 Social Links (Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.Get This Free Report This page (NASDAQ:RXDX) was last updated on 10/12/2025 by MarketBeat.com Staff From Our PartnersMagnificent 7 being replaced by the “Hidden 7”?BULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | SponsoredURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredMiss This IRS Strategy Now, Regret It LaterWith Donald Trump back in the White House, many believe an economic revival could be underway — but it also br...American Alternative | SponsoredRobinhood warningA strange chasm is coming to Wall Street... It's already creating millionaires and billionaires at the fast...Stansberry Research | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | Sponsored1 Hour Once A DayMy top income trading expert, Dave Aquino, just released a 1-hour trading strategy designed specifically to he...Base Camp Trading | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Prometheus Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Prometheus Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
